KYC is one time exercise with a SEBI registered intermediary while dealing in securities markets (Broker/ DP/ Mutual Fund etc.). | No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.   |   Prevent unauthorized transactions in your account – Update your mobile numbers / email ids with your stock brokers. Receive information of your transactions directly from exchange on your mobile / email at the EOD | Filing Complaint on SCORES - QUICK & EASY a) Register on SCORES b) Mandatory details for filing complaints on SCORE - Name, PAN, Email, Address and Mob. no. c) Benefits - speedy redressal & Effective communication   |   BSE Prices delayed by 5 minutes... << Prices as on Apr 17, 2025 >>  ABB India 5567.95  [ 3.52% ]  ACC 2061.55  [ 0.14% ]  Ambuja Cements 569.6  [ 0.66% ]  Asian Paints Ltd. 2469.65  [ 0.42% ]  Axis Bank Ltd. 1190.65  [ 2.51% ]  Bajaj Auto 8017.75  [ 0.71% ]  Bank of Baroda 242.7  [ 0.75% ]  Bharti Airtel 1889.2  [ 3.63% ]  Bharat Heavy Ele 227.5  [ 0.69% ]  Bharat Petroleum 298.25  [ -0.17% ]  Britannia Ind. 5453.05  [ 0.72% ]  Cipla 1515.45  [ 1.27% ]  Coal India 398.75  [ -0.15% ]  Colgate Palm. 2570.3  [ 0.73% ]  Dabur India 479.2  [ -0.44% ]  DLF Ltd. 669.8  [ 2.01% ]  Dr. Reddy's Labs 1163.7  [ 0.36% ]  GAIL (India) 186.95  [ 1.22% ]  Grasim Inds. 2760.7  [ 2.07% ]  HCL Technologies 1438.05  [ 0.41% ]  HDFC Bank 1906.55  [ 1.53% ]  Hero MotoCorp 3773.45  [ -0.24% ]  Hindustan Unilever L 2374.65  [ 0.32% ]  Hindalco Indus. 608.9  [ -0.16% ]  ICICI Bank 1406.65  [ 3.68% ]  Indian Hotels Co 841  [ -0.11% ]  IndusInd Bank 794.4  [ 0.78% ]  Infosys L 1420.2  [ 0.51% ]  ITC Ltd. 427.25  [ 0.73% ]  Jindal St & Pwr 882.8  [ 3.37% ]  Kotak Mahindra Bank 2188  [ 3.06% ]  L&T 3246.5  [ 0.57% ]  Lupin Ltd. 1936.75  [ 0.05% ]  Mahi. & Mahi 2679.35  [ 1.69% ]  Maruti Suzuki India 11691.3  [ 0.23% ]  MTNL 43.85  [ -0.16% ]  Nestle India 2415.6  [ 1.34% ]  NIIT Ltd. 130.55  [ 2.75% ]  NMDC Ltd. 65.9  [ 0.23% ]  NTPC 364.1  [ 1.34% ]  ONGC 243.55  [ 0.97% ]  Punj. NationlBak 99.51  [ 0.69% ]  Power Grid Corpo 308.8  [ 0.96% ]  Reliance Inds. 1274.55  [ 2.90% ]  SBI 797.1  [ 3.28% ]  Vedanta 400  [ 0.36% ]  Shipping Corpn. 175.4  [ 0.23% ]  Sun Pharma. 1751.05  [ 3.45% ]  Tata Chemicals 848.4  [ 0.09% ]  Tata Consumer Produc 1120.05  [ 1.31% ]  Tata Motors 621.5  [ 0.88% ]  Tata Steel 137.15  [ 0.15% ]  Tata Power Co. 381.35  [ 0.04% ]  Tata Consultancy 3298.95  [ 0.80% ]  Tech Mahindra 1305.85  [ -0.24% ]  UltraTech Cement 11903  [ 1.50% ]  United Spirits 1517.15  [ 1.01% ]  Wipro 236.9  [ -4.28% ]  Zee Entertainment En 114.29  [ 1.45% ]  
  • Share Prices
  • Tools
  • News
  • Company Details
  • Financial Data
  • Results
  • Key Financial Ratios
  • Reports
  • Corporate Announcements
  • Equity History

    • Company Information

    Indian Indices
    • Loading....

    Global Indices
    • Loading....

    Forex
    • Loading....

    SUN PHARMA ADVANCED RESEARCH COMPANY LTD.

    17 April 2025 | 12:00

    Industry >> Medical Research Services

    Select Another Company

    ISIN No INE232I01014 BSE Code / NSE Code 532872 / SPARC Book Value (Rs.) -2.38 Face Value 1.00
    Bookclosure 30/09/2020 52Week High 350 EPS 0.00 P/E 0.00
    Market Cap. 4865.55 Cr. 52Week Low 109 P/BV / Div Yield (%) -62.88 / 0.00 Market Lot 1.00
    Security Type Other

    History of Company

    The company history sections lists out major chronological events that happened to the company.
    2007 - Sun Pharma Advanced Research Co.Ltd was formed in the year 2007, with separation of India's leading specialty pharma company, Sun Pharmaceutical Industries Ltd, and its active projects in drug discovery and innovation into a new company. The parent company, Sun Pharma Industries Ltd continues to invest independently in generic research.

    - Sun Pharma Advanced Research Company Ltd (SPARCL) had allotted 3,39,441 equity shares of Re 1 each to the bond-holders of Sun Pharma Industries Ltd (SPIL) on conversion of 5,500 foreign currency convertible bonds upon conversion.

    - Balance Sheet along with the Profit and Loss Account for the year ended March 31, 2007 adopted and the Reports of Directors & Auditors thereon.

    - Mr. Dilip S Shanghvi and Mr. Sudhir V Valia, re appointed as the Directors of the Company.

    - According to the clause 10.2 of the scheme of arrangement of demerger, sanctioned by the High Court of Gujarat through its order dated March 01, 2007, issued on March 28, 2007 and as per supplementary Trust Deed dated may 18, 2007, the FCCB's holders of Sun Pharma Industries Ltd, are entitled for one equity share of Re 1 each of the company for every equity share of Rs.5 each of SPIL.

    2011

    - "Sun Pharma announces USFDA approval for DOCEFREZ (docetaxel) for Injection".

    2012

    -SPARC - Starhaler Device finalist at Medical Design Excellence Awards

    -Sun Pharma Advanced Research Company Ltd Issues Rights in the Ratio of 1:7

    2013 -SPARC to provide update on NCE & NDDS programs

    2014 -SPARC Announces India Approval for Paclitaxel Injection Concentrate for Nanodispersion (PICN)

    2017 - SPARC has received a Complete Response Letter (CRL) from the USFDA for its New Drug Application (NDA) for Elepsia XRTM, Levetiracetam extended-release tablets 1000 mg and 1500 mg.

    2018 -SPARC to provide progress on R&D Pipeline -Sun Pharma and SPARC Announce US FDA Approval of XELPROS to Treat Open-angle Glaucoma or Ocular Hypertension -SPARC Announces Top-line Results of Pivotal Bioequivalence Study for Paclitaxel Injection Concentrate for Suspension -Schr”dinger and SPARC Announce Collaboration to Accelerate Neurodegeneration Drug Development Program

    2019 -SPARC Enters into Licensing Agreement with Bioprojet to Acquire Exclusive Rights for Investigational -HitGen and SPARC Enter DNA-Encoded Library Based Innovative Drug Discovery Research Collaboration -SPARC Receives Orphan Drug Designation from the USFDA for SCO-088 for the Treatment of Patients with Chronic Myeloid Leukemia -SPARC Enters into a Licensing Deal with CMS -SPARC Enters into Licensing Agreement with Bioprojet to Acquire Exclusive Rights for Investigational Medicinal Product, SCD-044 2020 -Sun Pharma Advanced Research Company Ltd grant of an exclusive license to Tripoint Therapeutics LLC to commercialize ElepsiaTM XR 1000 mg and ElepsiaTM XR 1500 mg tablets in the USA. -Sun Pharma Advanced Research Company Ltd got positive top-line results from its Phase 3 trial for its investigational drug, SDN-037, for the treatment of Inflammation and Pain associated with Ocular Surgery -SPARC to Provide Update on Clinical Programs and R&D Pipeline

    2021 -SPARC enters into a licensing agreement with Biomodifying to acquire exclusive rights for antibody against unique oncology target -Sun Pharma Advanced Research Company Ltd has entered into an agreement with Visiox Pharma LLC to grant exclusive worldwide rights for the development and commercialization of PDP-716 and SDN-037

    2022 -Sun Pharma and SPARC enter into a license agreement for commercialization of phenobarbital for injection in the US.

    2023 -Entered into licensing agreement to acquire exclusive rights for SCD-153. -Formation of US subsidiary.

    Way2Wealth Brokers Private Limited - CIN U67120KA2000PTC027628 Stock Broking: SEBI Regn No.: INZ000178638 | Exchange Membership ID: NSE: 11502, BSE: 3117, MSEI:51000, MCX: 56730 Depository Participant: SEBI Regn No. IN-DP-472-2020 | CDSL ID: 12062900 & 12031500, NSDL ID: IN303077 PMS: SEBI Regn No.INP000000829 | Register with AMFI ARN: 77558 (Date of Initial registration - 8th Dec 2009, Date of expiry - 24th Jan 2027) | PFRDA: POP226012019

    Way2Wealth Commodities Private Limited - CIN U51229KA2006PTC039880 Stock Broking: SEBI Regn No.: INZ000049130 | Exchange Membership ID: NCDEX : 00908

    Copyrights @ 2014 © Way2Wealth Brokers Pvt. Ltd. All rights reserved

    Designed, developed and content provided by  Dion

    Procedure to file a complaint on SEBI SCORES: Register on SCORES portal. Mandatory details for filing complaints on SCORES: Name, PAN, Address, Mobile Number, E-mail ID. Benefits: Effective Communication, Speedy redressal of the grievances.